Comment

. 2022 Nov;77(5):1471-1472.

doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.

Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma

Si-Yu Liu¹, Chen Yuan², Xiang-Min Tong³

Affiliations

¹ Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China; The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Zhejiang, China.
² Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China.
³ Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China; The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Zhejiang, China. Electronic address: tongxiangminzry@outlook.com.

PMID: 35863489
DOI: 10.1016/j.jhep.2022.07.005

Comment

Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma

Si-Yu Liu et al. J Hepatol. 2022 Nov.

. 2022 Nov;77(5):1471-1472.

doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.

Authors

Si-Yu Liu¹, Chen Yuan², Xiang-Min Tong³

Affiliations

¹ Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China; The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Zhejiang, China.
² Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China.
³ Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Cancer Center, Affiliated People's Hospital of Hangzhou Medical College, Zhejiang Provincial People's Hospital, Zhejiang, China; The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Zhejiang, China. Electronic address: tongxiangminzry@outlook.com.

PMID: 35863489
DOI: 10.1016/j.jhep.2022.07.005

No abstract available

Keywords: Antiviral therapy; Hepatocellular carcinoma; Recurrence; Seroclearance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest All authors declared no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
Choi J. Choi J. J Hepatol. 2022 Nov;77(5):1472-1474. doi: 10.1016/j.jhep.2022.07.032. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35987276 No abstract available.

Comment on

Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
Yoo S, Kim JY, Lim YS, Han S, Choi J. Yoo S, et al. J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26. J Hepatol. 2022. PMID: 35643206

Cited by

ACTB may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study.
Dong W, Zou M, Sheng J, Zhou W, Wang Y, Zhang Y, Li J, Qian Y, Yu H, Lu T, Pan J, Zhu Y, Qu S, Yang Z, Lin Q, Zhao L, Cong W, Xu B, Zhang C, Liu H, Dong H. Dong W, et al. J Gastrointest Oncol. 2023 Dec 31;14(6):2479-2499. doi: 10.21037/jgo-23-942. Epub 2023 Dec 27. J Gastrointest Oncol. 2023. PMID: 38196518 Free PMC article.
Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.
Xu W, Gong H, Li B, Yin X. Xu W, et al. Ther Adv Med Oncol. 2024 Oct 18;16:17588359241289202. doi: 10.1177/17588359241289202. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39483138 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma

Affiliations

Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical